GENB ▼ -7.4% - Generate Biomedicines, Inc. $GENB Generate Biomedicines and ZEAL Zealand Pharma: Sign AI-Driven Obesity Drug Partnership Worth Up to Nearly $1.2 Billion in Milestones ? • Generate receives $30M upfront, with up to $35M in early preclinical milestones and tiered royalties on future sales. • Collaboration targets AI-engineered protein therapeutics for obesity and metabolic diseases, initially covering two programs with an option for a third. • Generate leads early research and candidate selection; Zealand handles clinical development, regulatory approvals and global commercialization. 13-OCT-2026 05:07 PM ET